FDA Clearance Tracker · P120005-S041
DEXCOM G5 MOBILE CONTINUOUS GLUCOSE MONITORING SYSTEM
Last checked: Nov 20, 2026Latest source record: Dec 20, 2016 (this decision)Source: openFDAMethods & limitations
Decided
Dec 20, 2016
Approved
Time to decision
452 days
Received Sep 25, 2015. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P120005-S041
- Device name
- DEXCOM G5 MOBILE CONTINUOUS GLUCOSE MONITORING SYSTEM
- Applicant
- Dexcom, Inc.
- Applicant location
- San Diego, CA
- Received
- Sep 25, 2015
- Decided
- Dec 20, 2016
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P120005
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for the Dexcom G5 Mobile Continuous Glucose Monitoring System (Dexcom G5) is a glucose monitoring system indicated for the management of diabetes in persons age 2 years and older. The Dexcom G5 is designed to replace fingerstick blood glucose testing for diabetes treatment decisions. Interpretation of the Dexcom G5 results should be based on the glucose trends and several sequential readings over time. The Dexcom G5 also aids in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments. The Dexcom G5 is intended for single patient use and requires a prescription.The G5 Mobile Continuous Glucose Monitoring System consists of the following devices: sensor, transmitter (with onboard algorithm), receiver, and mobile app. The sensor is a small flexible metal filament that is inserted into subcutaneous tissue where it enzymatically generates electrical current in response to the presence of glucose. The transmitter is connected to the sensor and is worn on the surface of the body. It samples the electrical current produced by the sensor and converts these measurements into glucose readings using an onboard algorithm. The transmitter sends glucose data to both the receiver and the mobile app and receives blood glucose calibration and other user inputs from these display devices. The receiver displays the current glucose reading (updated every 5 minutes) and glucose trends (up to 24 hours) from the transmitter. The receiver alerts the patient when glucose levels are outside of a target zone (factory set at 55 mg/dL, in addition to up to two user defined limits), when it is time to enter a blood glucose value from a fingerstick to calibrate the system, and for other important system conditions. The mobile app provides an alternative user interface to the receiver for those users with a compatible Apple iOS device. It provides similar glucose display, alert, and calibration functionality to the receiver and additionally provides connectivity to the Dexcom Share service.
Source documents
Other decisions for Dexcom, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K262472 · Decided Aug 11, 2026 · 25 days after receipt
Device type: Integrated Continuous Glucose Monitor For Non-Intensive Glucose Management, Over-The-Counter (SBH) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.